Silence Therapeutics Current Valuation vs. Net Income
| SLN Stock | USD 5.41 0.06 1.12% |
For Silence Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Silence Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Silence Therapeutics PLC utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Silence Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Silence Therapeutics PLC over time as well as its relative position and ranking within its peers.
Check out World Market Map. Will Biotechnology sector continue expanding? Could Silence diversify its offerings? Factors like these will boost the valuation of Silence Therapeutics. If investors know Silence will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Silence Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (1.35) | Revenue Per Share | Quarterly Revenue Growth (0.89) | Return On Assets | Return On Equity |
The market value of Silence Therapeutics PLC is measured differently than its book value, which is the value of Silence that is recorded on the company's balance sheet. Investors also form their own opinion of Silence Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Silence Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Silence Therapeutics' market value can be influenced by many factors that don't directly affect Silence Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Silence Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Silence Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Silence Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Silence Therapeutics PLC Net Income vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Silence Therapeutics's current stock value. Our valuation model uses many indicators to compare Silence Therapeutics value to that of its competitors to determine the firm's financial worth. Silence Therapeutics PLC is rated below average in current valuation category among its peers. It is currently regarded as top stock in net income category among its peers . Silence Therapeutics reported last year Net Loss of (40.78 Million). The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Silence Therapeutics' earnings, one of the primary drivers of an investment's value.Silence Current Valuation vs. Competition
Silence Therapeutics PLC is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is at this time estimated at about 1.43 Billion. Silence Therapeutics holds roughly 68.99 Million in current valuation claiming about 5% of equities under Health Care industry.
Silence Net Income vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Silence Therapeutics |
| = | 68.99 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Silence Therapeutics |
| = | (36.19 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Silence Net Income Comparison
Silence Therapeutics is currently under evaluation in net income category among its peers.
Silence Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Silence Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Silence Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Silence Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Silence Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -13.5 M | -12.9 M | |
| Operating Income | -57 M | -54.1 M | |
| Income Before Tax | -40 M | -38 M | |
| Total Other Income Expense Net | 21.7 M | 22.8 M | |
| Net Loss | -32.6 M | -30.9 M | |
| Income Tax Expense | 760.5 K | 798.5 K | |
| Net Interest Income | 5.1 M | 5.4 M | |
| Interest Income | 5.1 M | 5.4 M | |
| Net Loss | -40.8 M | -42.8 M | |
| Net Loss | -36.4 M | -38.3 M | |
| Change To Netincome | 3.2 M | 3.4 M | |
| Net Loss | (2.65) | (2.78) | |
| Income Quality | 1.68 | 1.77 | |
| Net Income Per E B T | 1.17 | 0.98 |
Silence Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Silence Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Silence Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Silence Therapeutics' important profitability drivers and their relationship over time.
Silence Therapeutics Earnings Estimation Breakdown
The calculation of Silence Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Silence Therapeutics is estimated to be -0.225 with the future projection ranging from a low of -0.44 to a high of -0.0825. Please be aware that this consensus of annual earnings estimates for Silence Therapeutics PLC is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.44 Lowest | Expected EPS | -0.08 Highest |
Silence Therapeutics Earnings Projection Consensus
Suppose the current estimates of Silence Therapeutics' value are higher than the current market price of the Silence Therapeutics stock. In this case, investors may conclude that Silence Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Silence Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 6 | 47.96% | 0.0 | -0.225 | -1.35 |
Silence Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of Silence Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Silence Therapeutics PLC predict the company's earnings will be in the future. The higher the earnings per share of Silence Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Silence Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Silence Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Silence Therapeutics should always be considered in relation to other companies to make a more educated investment decision.Silence Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Silence Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
null | null | null | null | null | 0 | ||
2025-11-13 | 2025-09-30 | -0.21 | -0.15 | 0.06 | 28 | ||
2025-08-07 | 2025-06-30 | -0.21 | -0.55 | -0.34 | 161 | ||
2025-05-08 | 2025-03-31 | -0.41 | -0.6 | -0.19 | 46 | ||
2025-02-27 | 2024-12-31 | -0.2452 | 0.17 | 0.4152 | 169 | ||
2024-11-14 | 2024-09-30 | -0.14 | -0.73 | -0.59 | 421 | ||
2024-08-15 | 2024-06-30 | -0.1145 | -0.4277 | -0.3132 | 273 | ||
2024-05-14 | 2024-03-31 | -0.1144 | -0.0541 | 0.0603 | 52 | ||
2024-03-13 | 2023-12-31 | -0.0778 | -0.4513 | -0.3735 | 480 | ||
2023-11-14 | 2023-09-30 | -0.17 | -0.07 | 0.1 | 58 | ||
2023-08-16 | 2023-06-30 | -0.1729 | -0.1224 | 0.0505 | 29 | ||
2023-05-16 | 2023-03-31 | -0.1504 | -0.1184 | 0.032 | 21 | ||
2023-03-15 | 2022-12-31 | -0.0124 | 0.4524 | 0.4648 | 3748 | ||
2022-11-10 | 2022-09-30 | -0.2011 | -0.0841 | 0.117 | 58 | ||
2022-09-14 | 2022-06-30 | -0.1961 | -0.1518 | 0.0443 | 22 | ||
2022-05-16 | 2022-03-31 | -0.1908 | -0.1054 | 0.0854 | 44 | ||
2022-03-17 | 2021-12-31 | -0.1417 | -0.1423 | -6.0E-4 | 0 | ||
2021-11-16 | 2021-09-30 | -0.152 | -0.149 | 0.003 | 1 | ||
2021-08-12 | 2021-06-30 | 0.8526 | -0.3147 | -1.1673 | 136 | ||
2021-06-02 | 2021-03-31 | -0.5542 | -0.5542 | 0.0 | 0 | ||
2021-03-31 | 2020-12-31 | 0 | -0.1568 | -0.1568 | 0 | ||
2020-12-31 | 2020-09-30 | 0 | -0.1774 | -0.1774 | 0 | ||
2020-09-30 | 2020-06-30 | 0 | -0.1419 | -0.1419 | 0 | ||
2020-06-30 | 2020-03-31 | 0 | -0.0848 | -0.0848 | 0 | ||
2020-03-31 | 2019-12-31 | 0 | -0.085 | -0.085 | 0 | ||
2019-12-31 | 2019-09-30 | 0 | -0.0953 | -0.0953 | 0 | ||
2019-09-30 | 2019-06-30 | 0 | -0.0885 | -0.0885 | 0 | ||
2019-06-30 | 2019-03-31 | 0 | -0.0732 | -0.0732 | 0 | ||
2019-03-31 | 2018-12-31 | 0 | -0.0751 | -0.0751 | 0 | ||
2018-12-31 | 2018-09-30 | 0 | -0.0878 | -0.0878 | 0 | ||
2018-09-30 | 2018-06-30 | 0 | -0.0898 | -0.0898 | 0 | ||
2018-06-30 | 2018-03-31 | 0 | -0.0819 | -0.0819 | 0 | ||
2018-03-31 | 2017-12-31 | 0 | -0.087 | -0.087 | 0 | ||
2017-12-31 | 2017-09-30 | 0 | 0.0376 | 0.0376 | 0 | ||
2017-09-30 | 2017-06-30 | 0 | 0.0373 | 0.0373 | 0 | ||
2017-06-30 | 2017-03-31 | 0 | -0.0514 | -0.0514 | 0 | ||
2017-03-31 | 2016-12-31 | 0 | -0.0495 | -0.0495 | 0 | ||
2016-12-31 | 2016-09-30 | 0 | -0.0327 | -0.0327 | 0 | ||
2016-09-30 | 2016-06-30 | 0 | -0.0344 | -0.0344 | 0 | ||
2016-06-30 | 2016-03-31 | 0 | -0.0451 | -0.0451 | 0 | ||
2016-03-31 | 2015-12-31 | 0 | -0.0488 | -0.0488 | 0 | ||
2015-12-31 | 2015-09-30 | 0 | -0.0264 | -0.0264 | 0 | ||
2015-09-30 | 2015-06-30 | 0 | -0.0271 | -0.0271 | 0 | ||
2015-06-30 | 2015-03-31 | 0 | -0.056 | -0.056 | 0 | ||
2015-03-31 | 2014-12-31 | 0 | -0.0529 | -0.0529 | 0 | ||
2014-12-31 | 2014-09-30 | 0 | -0.0817 | -0.0817 | 0 | ||
2014-09-30 | 2014-06-30 | 0 | -0.0851 | -0.0851 | 0 | ||
2014-06-30 | 2014-03-31 | 0 | -0.0986 | -0.0986 | 0 | ||
2014-03-31 | 2013-12-31 | 0 | -0.0961 | -0.0961 | 0 | ||
2013-12-31 | 2013-09-30 | 0 | -0.0984 | -0.0984 | 0 | ||
2013-09-30 | 2013-06-30 | 0 | -0.0962 | -0.0962 | 0 | ||
2013-06-30 | 2013-03-31 | 0 | -0.0635 | -0.0635 | 0 | ||
2013-03-31 | 2012-12-31 | 0 | -0.0634 | -0.0634 | 0 | ||
2012-12-31 | 2012-09-30 | 0 | -0.0805 | -0.0805 | 0 | ||
2012-09-30 | 2012-06-30 | 0 | -0.0799 | -0.0799 | 0 | ||
2012-06-30 | 2012-03-31 | 0 | -1.5985 | -1.5985 | 0 | ||
2012-03-31 | 2011-12-31 | 0 | -1.6297 | -1.6297 | 0 | ||
2011-12-31 | 2011-09-30 | 0 | -0.1546 | -0.1546 | 0 | ||
2011-09-30 | 2011-06-30 | 0 | -0.1553 | -0.1553 | 0 | ||
2011-06-30 | 2011-03-31 | 0 | -0.3908 | -0.3908 | 0 | ||
2011-03-31 | 2010-12-31 | 0 | -0.3905 | -0.3905 | 0 | ||
2010-12-31 | 2010-09-30 | 0 | -0.2428 | -0.2428 | 0 |
Use Silence Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Silence Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Silence Therapeutics will appreciate offsetting losses from the drop in the long position's value.Silence Therapeutics Pair Trading
Silence Therapeutics PLC Pair Trading Analysis
The ability to find closely correlated positions to Silence Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Silence Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Silence Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Silence Therapeutics PLC to buy it.
The correlation of Silence Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Silence Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Silence Therapeutics PLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Silence Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Silence Therapeutics position
In addition to having Silence Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Emerging Markets Funds Thematic Idea Now
Emerging Markets Funds
Fund or Etfs that invest in markets of developing countries. The Emerging Markets Funds theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Emerging Markets Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out World Market Map. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
To fully project Silence Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Silence Therapeutics PLC at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Silence Therapeutics' income statement, its balance sheet, and the statement of cash flows.